Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Royalty Corporation (NASDAQ: XOMA) operates as a biotechnology-focused royalty aggregator, providing non-dilutive funding to advance therapeutic development. This page serves as the definitive source for official company announcements and third-party analysis of XOMA's strategic partnerships, licensing agreements, and portfolio developments.
Investors and industry observers will find curated updates on milestone achievements, regulatory progress, and financial disclosures. Our aggregation includes press releases related to royalty acquisitions, clinical trial advancements, and commercial partnerships across XOMA's portfolio of innovative therapies.
The resource is particularly valuable for tracking payments tied to licensed assets in therapeutic areas including oncology and rare diseases. Users can expect updates on key business activities while avoiding promotional content or speculative analysis.
Bookmark this page for streamlined access to XOMA's latest developments. Combine regular visits with SEC filings and market data for comprehensive investment research.
XOMA Corporation (Nasdaq: XOMA) reported a strong financial performance for Q1 2022, with total revenues of $3.1 million, up from $0.4 million in Q1 2021. This increase was propelled by a $2 million milestone from Rezolute for the RZ358 study. The company concluded Q1 2022 with cash and restricted cash totaling $88.6 million and no debt. Notably, XOMA recognized a net loss of $2.3 million, a significant improvement compared to a $7.4 million loss in the prior year. The firm remains optimistic about its financial stability and future operations.
XOMA Corporation (Nasdaq: XOMA) announced cash dividends for holders of its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Cumulative Preferred Stock (Nasdaq: XOMAP) will receive $0.53906 per share, while holders of depositary shares representing 1/1000 of the Series B Cumulative Preferred Stock (Nasdaq: XOMAO) will receive $0.52344 per share. The dividends will be paid on or about April 15, 2022, to shareholders on record as of April 1, 2022.
On March 10, 2022, XOMA Corporation (Nasdaq: XOMA) announced that Chairman and CEO Jim Neal will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 17, 2022, at 12:40 PM ET. This virtual event can be accessed through a direct link or via the investor relations section of XOMA's website, where a replay will be available for 90 days. XOMA specializes in acquiring future royalties from pre-commercial therapeutic candidates, providing non-dilutive funding to biotech companies. The company has an extensive portfolio with over 70 assets.
XOMA Corporation (Nasdaq: XOMA) reported a strong financial performance in 2021, earning $36.2 million in milestone payments and achieving positive operating cash flow for the second consecutive year. Key highlights include a $35 million milestone from its Anti-TGFβ Antibody License Agreement with Novartis. Total revenues reached $38.2 million in 2021, up from $29.4 million in 2020. The company ended the year with $95.4 million in cash and no debt. Significant advances include commercialization approval for a bispecific antibody and progress in multiple drug candidates. CEO succession planning is underway.
XOMA Corporation, a biotechnology royalty aggregator, announced that its Chairman and CEO, Jim Neal, will participate in a fireside chat at the 42nd Annual Cowen Health Care Conference. The event is scheduled for March 7, 2022, at 1:30 PM ET. Investors can access the presentation live or via a replay on the company's website for 90 days post-event. XOMA plays a crucial role in advancing human health by acquiring potential future economics from pre-commercial therapeutic candidates, boasting a portfolio of over 70 assets.
XOMA Corporation (Nasdaq: XOMA) announced that its CEO, Jim Neal, will present at the Aegis Capital Corp Virtual Conference on February 24, 2022 at 11:00 AM ET. This event runs from February 23-25, 2022, showcasing biotech advancements. The presentation will be accessible via Aegis and on XOMA's investor relations website, with a replay available for 90 days. XOMA, a biotechnology royalty aggregator, specializes in acquiring future economics linked to drug candidates, helping biotech firms with funding to advance their projects.
XOMA Corporation announced cash dividends for holders of its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Preferred Stock will receive $0.53906 per share, while holders of the 8.375% Series B Cumulative Preferred Stock will receive $0.52344 per depositary share. These dividends will be paid on January 18, 2022, to shareholders of record as of January 4, 2022. XOMA continues to play a unique role in biotechnology by acquiring future economic rights to therapeutic candidates, supporting funding for developers.
XOMA Corporation (Nasdaq: XOMA) announced that CEO Jim Neal will present at two upcoming investor conferences. The first is the Biotech Showcase 2022, taking place virtually from January 10-12 and January 17-19, 2022, where Neal will participate in a fireside chat titled, “Royalty Licenses: An Economic Asset Often Ignored” on January 10 at 10:30 AM PT. The second conference is the H.C. Wainwright BioConnect Virtual Conference, held January 10-13, 2022, with a presentation available on-demand starting January 10 at 4:00 AM PT.
XOMA Corporation has appointed Jim Neal as Chairman of the Board, who will continue in his role until a new CEO is selected. Former Chairman, W. Denman Van Ness, will serve as Lead Independent Director. XOMA's portfolio includes over 70 assets in various stages of development, with significant recent milestones, including a $35 million payment from Novartis for advancing a candidate to Phase 3. XOMA maintains a debt-free balance sheet and expects to have nearly $100 million in cash following the Novartis milestone, positioning the company for continued growth.
XOMA Corporation (Nasdaq: XOMA) has announced a significant development as NIS793, an anti-TGFβ monoclonal antibody, progresses to Phase 3 trials, triggering a $35 million milestone payment from Novartis. The trial aims to evaluate NIS793's efficacy and safety in treating first-line metastatic pancreatic ductal adenocarcinoma. NIS793 has also received Orphan Drug Designation from the FDA. This milestone is part of a potential $410 million in milestone payments from Novartis, with tiered royalties on future sales based on successful commercialization.
FAQ
What is the current stock price of XOMA Royalty Corporation (XOMA)?
What is the market cap of XOMA Royalty Corporation (XOMA)?
